DalsnaFinance Account

IQVIA $IQV

Health Care · Life Sciences Tools & Services · NYSE/NASDAQ

S&P 500 Russell 1000 North Carolina

Create a scorecard

$262.01

+1.33 (+0.51%)

As of Oct 15, 2026, 1:24 AM EDT

Price history

Loading chart…

Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Oct 14, 2026, the first target we tracked for IQV.

IQVIA (IQV) is trading up at $262.01 (+0.51%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.

Analyst price targets on IQV

One firm's current price target on IQVIA: $303 — 16% above the current $262. Each is tracked to its date and scored the same way a member's call is.

Stifel $266 → $303 by Oct 2027 Buy Oct 14, 2026 via Investing.com · Stifel's track record

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

IQVIA revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)

IQVIA annual financial statements
	FY2016Dec 2016	FY2017Dec 2017	FY2018Dec 2018	FY2019Dec 2019	FY2020Dec 2020	FY2021Dec 2021	FY2022Dec 2022	FY2023Dec 2023	FY2024Dec 2024	FY2025Dec 2025
Income statement
Revenue	$6.88B	$9.74B	$10.4B	$11.1B	$11.4B	$13.9B	$14.4B	$15.0B	$15.4B	$16.3B
Growth (year over year)	+19.9%	+41.6%	+6.9%	+6.5%	+2.4%	+22.1%	+3.9%	+4.0%	+2.8%	+5.9%
Gross profit	$3.64B	$5.12B	$3.67B	$3.79B	$3.86B	$4.64B	$5.03B	$5.24B	$5.38B	$5.43B
Gross margin	53.0%	52.5%	35.2%	34.2%	34.0%	33.5%	34.9%	35.0%	34.9%	33.3%
Operating income	$576.0M	$665.0M	$741.0M	$777.0M	$731.0M	$1.39B	$1.80B	$1.98B	$2.20B	$2.18B
Operating margin	8.4%	6.8%	7.1%	7.0%	6.4%	10.0%	12.5%	13.2%	14.3%	13.4%
Net income	$72.0M	$1.28B	$259.0M	$191.0M	$279.0M	$966.0M	$1.09B	$1.36B	$1.37B	$1.36B
Net margin	1.0%	13.1%	2.5%	1.7%	2.5%	7.0%	7.6%	9.1%	8.9%	8.3%
EPS (diluted)	$0.47	$5.74	$1.24	$0.96	$1.43	$4.95	$5.72	$7.29	$7.49	$7.84
Balance sheet
Cash and equivalents	$1.20B	$959.0M	$891.0M	$837.0M	$1.81B	$1.37B	$1.22B	$1.38B	$1.70B	$1.98B
Total assets	$21.2B	$22.9B	$22.5B	$23.3B	$24.6B	$24.7B	$25.3B	$26.7B	$26.9B	$29.9B
Total liabilities	$12.3B	$14.6B	$15.6B	$17.0B	$18.3B	$18.6B	$19.6B	$20.6B	$20.8B	$23.3B
Long-term debt	$7.11B	$10.1B	$10.9B	$11.5B	$12.4B	$12.0B	$12.6B	$13.0B	$12.8B	$13.9B
Shareholders' equity	$8.63B	$8.00B	$6.71B	$6.00B	$6.00B	$6.04B	$5.76B	$6.11B	$6.07B	$6.50B
Cash flow
Operating cash flow	$860.0M	$970.0M	$1.25B	$1.42B	$1.96B	$2.94B	$2.26B	$2.15B	$2.72B	$2.65B
Capital expenditure	$164.0M	$369.0M	$459.0M	$582.0M	$616.0M	$640.0M	$674.0M	$649.0M	$602.0M	$603.0M
Free cash flow	$696.0M	$601.0M	$795.0M	$835.0M	$1.34B	$2.30B	$1.59B	$1.50B	$2.11B	$2.05B
Share buybacks	$1.10B	$2.62B	$1.41B	$949.0M	$447.0M	$406.0M	$1.17B	$992.0M	$1.35B	$1.24B

RevenueNet incomeNet margin (right axis, %)

IQVIA quarterly financial statements
	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24^†Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25^†Dec 2025	Q1 FY26Mar 2026
Income statement
Revenue	$3.81B	$3.90B	$3.96B	$3.83B	$4.02B	$4.10B	$4.36B	$4.15B
Growth (year over year)	+2.3%	+4.3%	+2.3%	+2.5%	+5.3%	+5.2%	+10.3%	+8.4%
Gross profit	$863.0M	$915.0M	$2.77B	$1.30B	$1.32B	$1.37B	$1.44B	$1.35B
Gross margin	22.6%	23.5%	70.0%	33.9%	32.9%	33.5%	32.9%	32.6%
Operating income	$520.0M	$550.0M	$626.0M	$496.0M	$506.0M	$553.0M	$627.0M	$514.0M
Operating margin	13.6%	14.1%	15.8%	13.0%	12.6%	13.5%	14.4%	12.4%
Net income	$363.0M	$285.0M	$437.0M	$249.0M	$266.0M	$331.0M	$514.0M	$274.0M
Net margin	9.5%	7.3%	11.0%	6.5%	6.6%	8.1%	11.8%	6.6%
EPS (diluted)	$1.97	$1.55	$2.41	$1.40	$1.54	$1.93	$2.97	$1.61
Balance sheet
Cash and equivalents	$1.54B	$1.57B	$1.70B	$1.74B	$2.04B	$1.81B	$1.98B	$1.95B
Total assets	$26.4B	$27.2B	$26.9B	$27.3B	$28.6B	$28.7B	$29.9B	$29.7B
Total liabilities	$19.7B	$20.2B	$20.8B	$21.3B	$22.8B	$22.4B	$23.3B	$23.3B
Long-term debt	$12.1B	$12.3B	$12.8B	$13.1B	$14.2B	$12.8B	$13.9B	$14.0B
Shareholders' equity	$6.71B	$6.97B	$6.07B	$5.98B	$5.78B	$6.16B	$6.50B	$6.22B
Cash flow
Operating cash flow	$588.0M	$721.0M	$885.0M	$568.0M	$443.0M	$908.0M	$735.0M	$618.0M
Capital expenditure	$143.0M	$150.0M	$164.0M	$142.0M	$151.0M	$136.0M	$174.0M	$127.0M
Free cash flow	$445.0M	$571.0M	$721.0M	$426.0M	$292.0M	$772.0M	$561.0M	$491.0M
Share buybacks	$0	$200.0M	$1.15B	$375.0M	$657.0M	$0	$212.0M	$552.0M

From IQVIA's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

About IQVIA

IQVIA Holdings, Inc. is an American health information technology and clinical research company headquartered in Durham, North Carolina. The company provides clinical research services, healthcare analytics, technology solutions, and commercial outsourcing services to pharmaceutical, biotechnology, medical device, and healthcare organizations worldwide.

Source: Wikipedia — IQVIA